The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines.

After 18 h, a large amount of PC3 treated cells was still present in late S and G2/M phase, whereas LNCaP, as expected, showed a trend to accumulate in S phase ( Figure 2C ).

also in 53,322 other papers